An MHRA inspection should never feel like a last-minute scramble. In reality, inspection readiness is built well before the inspection letter arrives. The strongest organisations are not the ones with the neatest slide deck on the day; they are the ones that can clearly demonstrate that their systems, records, decisions and oversight have been working in practice all along.
In the UK, MHRA GCP inspections are largely conducted under a risk-based programme and may be systems-based or trial-specific. Where an organisation is selected for routine inspection, MHRA requests a GCP inspection dossier and clinical trials spreadsheet, typically within 30 days. The agency also expects the complete TMF to be available, including electronic records and relevant emails, and makes clear that sponsors who subcontract activities may still need to provide the TMF and supporting documentation themselves. (GOV.UK)
That point is critical. Too many sponsors assume inspection readiness sits mainly with the CRO, Service Providers or operational team. It does not. Inspection readiness is a sponsor responsibility, even in heavily outsourced models. If oversight has been weak, fragmented or poorly documented, an inspection will expose that very quickly.
A practical way to prepare is to focus on five areas.
First, make sure your governance is visible. Roles, responsibilities, escalation routes and decision-making should be clear and documented. Second, test your TMF, not just for presence of documents, but for completeness, timeliness and accessibility. Third, review Service Providers oversight evidence. You should be able to demonstrate how you qualified providers, how performance was reviewed, and how issues were escalated and followed through. Fourth, prepare your subject matter experts for interviews. Inspectors do not just review documents; they test whether your processes are understood and actually being followed. Fifth, identify and address known weaknesses before the inspection rather than hoping they will not be seen.
This has become even more important with the UK’s implementation of ICH E6(R3). MHRA states that compliance with the ICH E6 GCP principles became a legal requirement in the UK on 28 April 2026, and that sponsors and investigators must give due regard to the Annexes as relevant guidance. The same guidance also makes clear that sponsor functions include areas such as trial-specific computerised systems and oversight of laboratories involved in analysing human samples collected in the trial. (GOV.UK)
A good inspection host does not try to “perform” compliance. They demonstrate it. MHRA’s own inspectorate has said the aim is not to catch organisations out, but to verify that participant safety is protected and that decisions are based on robust data. That is the mindset sponsors should adopt internally as well. (mhrainspectorate.blog.gov.uk)
Preparing for an MHRA inspection is therefore not about creating a perfect inspection week. It is about making sure your study oversight, documentation, systems and quality culture are inspection-ready every day.
MSAQS supports sponsors and service providers with inspection readiness reviews, Service Providers oversight assessments and practical QA support ahead of regulatory inspections.
